Close 2026-08-21 1267 scanned A

ONESOURCE

Onesource Specialty Pharma Limited
HealthcareMid capRs 17,597 crRs 35.7 cr traded a day
Close on 2026-08-21
1,535.00
+0.03%
52-week range54% of the way up
1,114.001,899.00
Market cap
17,597 cr
Revenue YoY
+37.2%
Q1 FY27
Net margin
5.6%
+5.6pt vs a year ago
Growth trend
+36.7pt
vs last quarter’s YoY
1 month
-7.2%
Below 52w high
23.7%
RSI (14)
45
Daily swing
3.1%
average true range
Volume
0.2×
vs 20-day average
Traded
Rs 36 cr
median day
Close200-day averageMaterial filing
1,2501,5001,750Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
−1.55%
1 month
−7.21%
3 months
−14.99%
6 months
+16.05%
1 year
−18.96%

The read

written from the numbers on this page
The evidence is mixed3 supporting, 3 against, 0 worth knowing

Supporting

  • 4 independent kinds of evidence agree today, which is uncommon
  • revenue grew 37% year on year in the quarter ending 2026-06-30
  • net margin has widened from 2.8% to 5.6% across four quarters

Against

  • trading 3% below its 200-day average
  • down 19% over twelve months
  • 2 of the scans it matches have historically underperformed the market

Worth knowing

  • nothing the data supports either way
What would change this read: a close back above 1,587, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

read from the filings, with the figure behind every line
Working2

Net margin improved from -0.1% to 5.6%.

-0.1%5.6%

Revenue rose 37.2% year on year, from Rs 327 cr to Rs 449 cr.

+37.2%Rs 327 crRs 449 cr
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. Wording of 2 of these 2 lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.

How it has performed

price return over each window, measured against zero
-1.6%1W-7.2%1M-15.0%3M+16.1%6M-19.0%1Y

What the scans say today

6 of 47 matched on 2026-08-21
ONESOURCE matches 6 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Recent filings

from the exchange, newest first
Credit rating filings were typically +0.58pt vs the market over the next 5 sessions (n=266) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
68393426327376290428449-57.8%23.1%5.6%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 37% against the same quarter a year earlier
  • net margin widened from 1.1% to 5.6%
  • revenue rose in 3 of the last 4 quarters

Going against it

  • profit dropped 13539% year on year
  • the company has not been profitable over the last four filed quarters
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
44920252.185.6%
Q4 FY26
2026-03-31 · consolidated
428-050.401.1%
Q3 FY26
2025-12-31 · consolidated
290-93-89-30.6%
Q2 FY26
2025-09-30 · consolidated
3766100.922.8%
Q1 FY26
2025-06-30 · consolidated
327-4-0-0.1%
Q4 FY25
2025-03-31 · consolidated
42684988.6123.1%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-4.9%
Versus 200-day average-3.3%
Below 52-week high-19.2%
Above 52-week low+37.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)45.0
Higher closes in last 52 of 5
Six-month return+16.05%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.14%
Volume versus 20-day0.2x
Median daily turnoverRs 35.7 cr

Peers

Healthcare · 67 classified companies
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
ONESOURCE17,597−7.21%−18.96%35.7
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
2026-08-181Lost the 200-day line